ScreenerHero

APVOAptevo Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · aptevotherapeutics.com
2.680USD-1.83%Mkt Cap: 4.83M $P/E: 0.01

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.83M $
Enterprise Value-6.44M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-25.97M $
Revenue/Share—
Last Price2.680 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees33
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS03835L2079
Valuation
P/E (Trailing)0.01
P/E (Forward)-0.27
PEG—
EV/EBITDA0.24
EV/Revenue—
P/S—
P/B0.16
EPS (TTM)456.62
EPS (Forward)-10.40
52W Range
2.5800% of range48.78
52W High48.78 USD
52W Low2.580 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-149.40%
ROA-95.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.59M $
CapEx (TTM)—
FCF Margin—
FCF Yield-356.10%
Net Debt-10.10M $
Net Debt/EBITDA0.38
Balance Sheet
Debt/Equity0.27
Current Ratio3.36
Quick Ratio3.05
Book Value/Sh17.42 USD
Cash/Share11.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 27, 2020
Splits
Last Split1:18
Split DateDec 30, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)25.50 USD
Upside (mean)+851.5%
Target Range21.00 USD – 30.00 USD
$21.00+851.5% to mean$30.00
# Analysts2
Ownership
Shares Out.1.80M
Float1.14M
Insiders6.79%
Institutions3.44%
Short Interest
Short Ratio1.0d
Short % Float5.78%
Short % Out.5.77%
Shares Short87.63K
Short (prev mo.)79.44K
Technical
SMA 504.217 (-36.5%)
SMA 2008.727 (-69.3%)
Beta1.65
S&P 52W Chg18.16%
Avg Vol (30d)38.58K
Avg Vol (10d)55.08K
Technical Indicators
RSI (14)23.3
MACD-0.4112
MACD Signal-0.2697
MACD Hist.-0.1415
BB Upper4.952 USD
BB Middle3.805 USD
BB Lower2.657 USD
BB Width60.31%
ATR (14)0.2793 USD
Vol Ratio (20d)1.77x